Merck (NYSE:MRK) recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecasts for the full year 2019. You can view our interactive
Surging sales of vaccines and the cancer immunotherapy drug Keytruda led to a quadrupling of profit at Merck during the first quarter as it blew past Wall Street expectations. Sales of Keytruda jumped
Merck (NYSE:MRK) is expected to publish its Q1 2019 results on April 30. This note details Trefis’ forecasts for Merck, as well as some of the key trends we will be watching when the company reports earnings.